Buy / Sell Syngene Intl share
Recommended ArticlesView All
Budget 2023: Aiming to establish India as skill capital of the world
Feb 3, 2023 IST5 Min(s) Read
Budget 2023: New Income Tax slab — A tectonic shift indeed in favour of the middle class
Feb 3, 2023 IST4 Min(s) Read
Budget 2023: Taking a bold step to unlock India’s potential
Feb 2, 2023 IST2 Min(s) Read
Budget 2023: Moving closer towards universal health through proper implementation is key
Feb 2, 2023 IST3 Min(s) Read
However, it was the second straight quarter when Syngene managed to grow its revenue by more than 20 percent.
Profit after tax (PAT) inched up 5 percent to Rs 110 crore compared to Rs 104 crore in the year-ago quarter. This was below Axis Capital's estimate of Rs 119.2 crore but in line with the company's guidance of single-digit growth for the quarter.
Operating income, or EBITDA, rose 14 percent to Rs 231 crore compared to Rs 203.4 crore a year ago. However, EBITDA margins slipped to 30.9 percent from 33.1 percent in the same period a year ago.
The company also said that it is maintaining its July 2022 upgraded guidance for the current fiscal i.e. high-teen revenue growth, EBITDA margin of around 30 percent, and profit growth in single digits for the full fiscal year.
Syngene International Ltd. is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors.